These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30670421)

  • 1. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
    Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
    Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
    White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
    Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
    Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
    Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
    Purchase SE; Garcia-Prats AJ; De Koker P; Draper HR; Osman M; Seddon JA; Schaaf HS; Hesseling AC
    Pediatr Infect Dis J; 2019 Jun; 38(6):608-610. PubMed ID: 30550511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
    Thee S; Garcia-Prats AJ; McIlleron HM; Wiesner L; Castel S; Norman J; Draper HR; van der Merwe PL; Hesseling AC; Schaaf HS
    Antimicrob Agents Chemother; 2014 May; 58(5):2948-51. PubMed ID: 24550337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.
    van der Laan LE; Hesseling AC; Schaaf HS; Palmer M; Draper HR; Wiesner L; Denti P; Garcia-Prats AJ
    J Antimicrob Chemother; 2023 Oct; 78(10):2481-2488. PubMed ID: 37596982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical and psychosocial challenges faced by caregivers influence the acceptability of multidrug-resistant tuberculosis preventive therapy for young children.
    Wademan DT; Hoddinott G; Purchase SE; Seddon JA; Hesseling AC; Garcia-Prats AJ; Reis R; Reynolds LJ
    PLoS One; 2022; 17(7):e0268560. PubMed ID: 35834509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Induced Fulminant Hepatitis in a Child Treated for Latent Multidrug-Resistant Tuberculosis With Dual Therapy Combining Pyrazinamide and Levofloxacin.
    Huguet A; Ader F; Ohlmann C; Collardeau-Frachon S; Gillet Y
    Pediatr Infect Dis J; 2019 Oct; 38(10):1025-1026. PubMed ID: 31335574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
    Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
    J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.
    Garcia-Prats AJ; Draper HR; Finlayson H; Winckler J; Burger A; Fourie B; Thee S; Hesseling AC; Schaaf HS
    Clin Infect Dis; 2018 Nov; 67(11):1777-1780. PubMed ID: 29788331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
    Mase SR; Jereb JA; Gonzalez D; Martin F; Daley CL; Fred D; Loeffler AM; Menon LR; Bamrah Morris S; Brostrom R; Chorba T; Peloquin CA
    Pediatr Infect Dis J; 2016 Apr; 35(4):414-21. PubMed ID: 26658531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
    Kempker RR; Barth AB; Vashakidze S; Nikolaishvili K; Sabulua I; Tukvadze N; Bablishvili N; Gogishvili S; Singh RS; Guarner J; Derendorf H; Peloquin CA; Blumberg HM
    Antimicrob Agents Chemother; 2015; 59(6):3149-55. PubMed ID: 25779583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoroquinolones for the treatment of tuberculosis in children.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.